Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease

被引：60

作者：

Koutroumpas, Athanasios ^{[1
]}

Ziogas, Athanasios ^{[1
]}

Alexiou, Ioannis ^{[1
]}

Barouta, Georgia ^{[1
]}

Sakkas, Lazaros I. ^{[1
]}

机构：

[1] Thessaly Univ, Sch Med, Dept Rheumatol, Larisa 41110, Greece

来源：

CLINICAL RHEUMATOLOGY | 2010年 / 29卷 / 10期

关键词：

Interstitial lung disease; Mycophenolate mofetil; Systemic sclerosis; IMATINIB;

D O I：

10.1007/s10067-010-1498-z

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

This study aimed to assess the effect of mofetil mycophenolate (MMF), an inhibitor of lymphocyte proliferation, on lung function and skin in patients with systemic sclerosis (SSc)-associated interstitial lung disease (SSc-ILD). In this retrospective study, we reviewed the medical files of 10 patients with SSc-ILD (eight females, 10 patients with diffuse SSc; mean age, 59.7 +/- 12.7 years; disease duration, 7.7 +/- 4.7 years). Patients were treated with MMF (2 g/day) for 12 months. Lung function tests and the modified Rodnan total skin score (mRTSS) were assessed at baseline and at 12 months. Results were analyzed by paired Student's t test. There was a significant increase in forced vital capacity and a nonsignificant increase in carbon monoxide diffusing capacity at 12 months in patients on MMF (p = 0.04 and 0.66, respectively). There was no effect on mRTSS. MMF stabilizes lung function of SSc-ILD after 12 months of treatment.

引用

页码：1167 / 1168

页数：2

共 14 条

[1]

Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study [J].

Daoussis, Dimitrios ;

Liossis, Stamatis-Nick C. ;

Tsamandas, Athanassios C. ;

Kalogeropoulou, Christina ;

Kazantzi, Alexandra ;

Sirinian, Chaido ;

Karampetsou, Maria ;

Yiannopoulos, Georgios ;

Andonopoulos, Andrew P. .

RHEUMATOLOGY, 2010, 49 (02) :271-280

[2]

Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease [J].

Gerbino, Anthony J. ;

Goss, Christopher H. ;

Molitor, Jernj A. .

CHEST, 2008, 133 (02) :455-460

[3]

LONGITUDINAL CHANGES IN LUNG-FUNCTION AND RESPIRATORY SYMPTOMS IN PROGRESSIVE SYSTEMIC-SCLEROSIS - PROSPECTIVE-STUDY [J].

GREENWALD, GI ;

TASHKIN, DP ;

GONG, H ;

SIMMONS, M ;

DUANN, S ;

FURST, DE ;

CLEMENTS, P .

AMERICAN JOURNAL OF MEDICINE, 1987, 83 (01) :83-92

[4]

B Cell Depletion With Rituximab in Patients With Diffuse Cutaneous Systemic Sclerosis [J].

Lafyatis, Robert ;

Kissin, Eugene ;

York, Michael ;

Farina, Giuseppina ;

Viger, Kerry ;

Fritzler, Marvin J. ;

Merkel, Peter A. ;

Simms, Robert W. .

ARTHRITIS AND RHEUMATISM, 2009, 60 (02) :578-583

[5]

Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease [J].

Liossis, S. N. C. ;

Bounas, A. ;

Andonopoulos, A. P. .

RHEUMATOLOGY, 2006, 45 (08) :1005-1008

[6]

A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamide [J].

Sabnani, I. ;

Zucker, M. J. ;

Rosenstein, E. D. ;

Baran, D. A. ;

Arroyo, L. H. ;

Tsang, P. ;

Zubair, M. ;

Rivera, V. .

RHEUMATOLOGY, 2009, 48 (01) :49-52

[7]

Imatinib for the treatment of refractory, diffuse systemic sclerosis [J].

Sfikakis, P. P. ;

Gorgoulis, V. G. ;

Katsiari, C. G. ;

Evangelou, K. ;

Kostopoulos, C. ;

Black, C. M. .

RHEUMATOLOGY, 2008, 47 (05) :735-737

[8]

SEVERE RESTRICTIVE LUNG-DISEASE IN SYSTEMIC-SCLEROSIS [J].

STEEN, VD ;

CONTE, C ;

OWENS, GR ;

MEDSGER, TA .

ARTHRITIS AND RHEUMATISM, 1994, 37 (09) :1283-1289

[9]

THE EFFECT OF D-PENICILLAMINE ON PULMONARY FINDINGS IN SYSTEMIC-SCLEROSIS [J].

STEEN, VD ;

OWENS, GR ;

REDMOND, C ;

RODNAN, GP ;

MEDSGER, TA .

ARTHRITIS AND RHEUMATISM, 1985, 28 (08) :882-888

[10]

Changes in causes of death in systemic sclerosis, 1972-2002 [J].

Steen, Virginia D. ;

Medsger, Thomas A. .

ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (07) :940-944

← 1 2 →